AT1.ASX: Response to ASX Price Query

Response to ASX Price Query

Stock	Atomo Diagnostics Ltd (AT1.ASX)
Release Time	25 Mar 2026, 5:07 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Atomo Diagnostics Responds to ASX Price Query

Key Points

Company unaware of any price-sensitive information not yet announced
Lumos Diagnostics' FebriDx CLIA waiver application update pending
Atomo to continue engagement with Lumos and provide market update

Full Summary

Atomo Diagnostics Limited has responded to an ASX price query regarding the recent trading in its securities. The company stated that it is not aware of any price-sensitive information that has not been announced to the market, which could explain the recent trading activity. Atomo noted that Lumos Diagnostics Holdings Ltd (ASX: LDX) has entered a trading halt pending an announcement related to an update on the FDA response to the FebriDx® CLIA waiver application. As previously disclosed, the FebriDx® test exclusively utilizes Atomo's patented Pascal cassette. Atomo confirmed that it is currently unaware of the details of the FDA's response regarding the FebriDx® CLIA waiver application and is unable to determine the impact on the company. However, Atomo stated that it will continue to engage with Lumos and provide an update to the market when possible. The company also confirmed that it is in compliance with the disclosure provisions of the Listing Rules, particularly Listing Rule 3.1.